⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PALI News
Palisade Bio, Inc. Common Stock
Palisade Bio Presents New Clinical, Pharmacokinetic, Pharmacodynamic and Mechanistic Data Strengthening the Phase 2 Rationale for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at ACG 2026
globenewswire.com
PALI
Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at UEG Week 2026
globenewswire.com
PALI
Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance
globenewswire.com
PALI
Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn’s Disease, Expanding Phase 2 Development Across IBD
globenewswire.com
PALI
Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
globenewswire.com
PALI
Palisade Bio to Participate in Upcoming Investor Conferences
globenewswire.com
PALI
Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development
globenewswire.com
PALI
Form 8-K
sec.gov
PALI
Palisade Bio to Participate in the Leerink Partners Therapeutics Forum
globenewswire.com
PALI
Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis
globenewswire.com
PALI